Data
- - - Truveta Data
      
      A complete, living view of patient care
    - Explore Truveta Data
  - - Capabilities
      
      Representative, complete, and real-time
  - - Therapeutic areas
      
      Explore every disease with longitudinal, clinical context
    - All therapeutic areas
    - Featured therapeutic areas
  - - Evidence
      
      Build trust through rigorous analytics and expertise
    - - Trusted research environment
      - Evidence Services
Intelligence
- - - Truveta Intelligence
      
      Answers in minutes, not months
    - Explore Truveta Intelligence
  - - Capabilities
      
      Ask what matters now
    - - Ask
  - - Evidence
      
      Verify the methodology behind the results
    - - Verify
Customers
- - - Truveta customers
      
      Trusted by leading life science, public health, and healthcare organizations
  - - Who we serve
Research
About
- - - Saving Lives with Data
      
      Built with and owned by US health systems to improve patient care
Contact us
Sign in



Close

Research

Featured research

C-section pain management study thumbnail image in Truveta branding.

Pain management after C-section: Following the journey from hospital to home

Pain medication use was nearly universal in the hospital, with more than 9 in 10 C-sections including acetaminophen, an NSAID, and an opioid. After discharge, NSAIDs and opioids were prescribed after about 6 in 10 C-sections and acetaminophen after about half. The...

Rising rate of non-receipt of vitamin K for newborns, January 2019–June 2026

Rising rate of non-receipt of vitamin K for newborns, 2019–June 2026

Truveta Research finds documented newborn vitamin K non-receipt rose from 5.2% in January to 8.1% in June 2026, continuing a recent upward trend.

Graphic from Truveta showing a record increase in GLP-1 prescribing among older adults following the launch of Medicare's GLP-1 Bridge program, with trend lines illustrating prescribing growth over time.

Older adults see record increase in GLP-1 prescribing following Medicare GLP-1 Bridge program

New Truveta research shows GLP-1 prescribing among adults 65+ rose 19% in July 2026, a record increase after Medicare’s GLP-1 Bridge launch.

Truveta research graphic titled '2026 Cyclosporiasis Outbreak: Diagnoses Reach Historic Levels,' featuring outbreak trend lines that illustrate a significant rise in cyclospora diagnoses during summer 2026

Cyclosporiasis diagnoses reach historic levels in 2026 summer outbreak

Real-world data reveal record cyclosporiasis diagnoses during the 2026 summer outbreak and support faster outbreak monitoring.

Featured research topics

GLP-1

Oncology

Flu/RSV

Measles

Cardiovascular